Core Viewpoint - The company and its wholly-owned subsidiary have received approval for two generic drugs, which is expected to enhance market expansion and sales opportunities [1] Group 1: Drug Approvals - The company received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for Azithromycin Tablets and Dihydrocodeine Injection [1] - Both drugs have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Market Potential - Azithromycin Tablets are indicated for infections caused by sensitive bacteria, with projected sales of 685 million yuan in public medical institutions and urban pharmacies in 2024 [1] - Dihydrocodeine Injection is used for treating bronchial asthma, with expected sales of 135 million yuan in public medical institutions in 2024 [1] - The successful evaluation is beneficial for product market expansion and sales [1]
国药现代:阿奇霉素片和二羟丙茶碱注射液通过仿制药一致性评价